These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11119065)

  • 1. [Approach to cognitive disorders in multiple sclerosis. Relationships between handicap and MRI findings].
    Pelletier J
    Rev Neurol (Paris); 2000 Nov; 156(11):1052-3. PubMed ID: 11119065
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification and management of cognitive disorders in multiple sclerosis--a consensus approach.
    Lensch E; Matzke M; Petereit HF; Scherer P; Schramm S; Calabrese P
    J Neurol; 2006 Feb; 253 Suppl 1():I29-31. PubMed ID: 16477483
    [No Abstract]   [Full Text] [Related]  

  • 3. Cognitive changes in multiple sclerosis.
    Amato MP; Zipoli V; Portaccio E
    Expert Rev Neurother; 2008 Oct; 8(10):1585-96. PubMed ID: 18928350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Magnetic resonance imaging correlates of cognitive dysfunction in patients with multiple sclerosis].
    Filippi M
    Rev Neurol; 2000 Jun 16-30; 30(12):1253-6. PubMed ID: 10935260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of impaired cognition in multiple sclerosis.
    Enzinger C
    Neurol India; 2006 Dec; 54(4):349. PubMed ID: 17114835
    [No Abstract]   [Full Text] [Related]  

  • 6. MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction.
    Rovaris M; Comi G; Filippi M
    J Neurol Sci; 2006 Jun; 245(1-2):111-6. PubMed ID: 16626748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
    Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
    Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benign or not benign MS: a role for routine neuropsychological assessment?
    Benedict RH; Fazekas F
    Neurology; 2009 Aug; 73(7):494-5. PubMed ID: 19641172
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive impairment and structural brain damage in benign multiple sclerosis.
    Rovaris M; Riccitelli G; Judica E; Possa F; Caputo D; Ghezzi A; Bertolotto A; Capra R; Falautano M; Mattioli F; Martinelli V; Comi G; Filippi M
    Neurology; 2008 Nov; 71(19):1521-6. PubMed ID: 18815387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive structural and functional MRI footprint for cognitive dysfunction in pediatric MS?
    Tedeschi G; Gallo A; Barkhof F
    Neurology; 2014 Apr; 82(15):1296-7. PubMed ID: 24647025
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks.
    Penner IK; Rausch M; Kappos L; Opwis K; Radü EW
    J Neurol; 2003 Apr; 250(4):461-72. PubMed ID: 12700913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cognition assessment in multiple sclerosis: difficulties in methodology and assessment protocols].
    Defer GL
    Rev Neurol (Paris); 2000 Nov; 156(11):1054-6. PubMed ID: 11119066
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain activation patterns elicited by the 'Faces Symbol Test' -- a pilot fMRI study.
    Grabner R; Popotnig F; Ropele S; Neuper C; Gorani F; Petrovic K; Ebner F; Strasser-Fuchs S; Fazekas F; Enzinger C
    Mult Scler; 2008 Apr; 14(3):354-63. PubMed ID: 18208887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.
    Bagnato F; Ohayon JM; Ehrmantraut M; Chiu AW; Riva M; Ikonomidou VN
    Expert Rev Neurother; 2006 Apr; 6(4):599-612. PubMed ID: 16623658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The application of magnetic resonance imaging transfer to the study of multiple sclerosis patients: review and analysis of literature].
    Grimaud J; Zhou LQ; Zhu YM
    Rev Neurol (Paris); 2002 Dec; 158(12 Pt 1):1157-73. PubMed ID: 12690734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cognitive impairment in multiple sclerosis patients].
    Zivadinov R; Sepcić J
    Lijec Vjesn; 2004; 126(7-8):204-10. PubMed ID: 15754791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Applicability of P300 potential in evaluation of cognitive processes in children and adolescents].
    Galas-Zgorzalewicz B
    Przegl Lek; 2006; 63 Suppl 1():1-3. PubMed ID: 17474172
    [No Abstract]   [Full Text] [Related]  

  • 20. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
    Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
    J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.